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Summary:
We investigated bone marrow (BM) and circulating
(PB) hematopoietic progenitor cells in 37 normal donors
and in 25 patients 1 to 8 years after successful allogeneic
bone marrow transplant. At the time of testing, trans-
planted patients had normal blood counts and bone
marrow cellularity. By flow cytometry, BM CD34+ cells
were found to be three- to four-fold decreased in trans-
planted patients compared to normal donors, while the
number of PB CD34+ cells was the same as in normal
donors. Using a methylcellulose colony assay, primary
BM colony-forming cells (CFU-GM) were decreased
2.1-fold, whereas PB CFU-GM were only marginally
decreased. In a long-term culture initiating cell (LTC-
IC) assay, an eight-fold decrease of early progenitor
cells was observed in the marrow of transplanted
patients compared to normal donors, and a five-fold
decrease was documented in peripheral blood. We
found that the BM LTC-IC cell number correlated with
concurrently determined BM CD34+ cells and commit-
ted progenitor cell number (measured as CFU-GM) and
with PB LTC-IC number, but not with PB CFU-GM
and CD34+ cells. We conclude that marrow and circul-
ating early stem cell compartments, as measured by the
LTC-IC assay, are greatly and permanently depressed
following bone marrow transplant. The correlation
between BM and PB LTC-IC indicates that the enumer-
ation of circulating LTC-IC can be used as a measure
of the stem cell compartment in the bone marrow after
transplant. It seems that the deficiency of the most
immature progenitor cells persists forever after success-
ful bone marrow transplant; this means that a complete
hematopoietic reconstitution can be sustained by a
reduced stem cell pool.
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Long-term survivors after allogeneic bone marrow trans-
plantation (BMT) have normal marrow cellularity and nor-
mal peripheral blood cell counts. Due to intrinsic experi-
mental problems with measurement of the human stem cell
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compartment, the majority of studies on stem and progeni-
tor cells after BMT deal only with more mature committed
colony forming-units (CFU-GM).1–3 These studies suggest
that the recovery of committed progenitors such as CFU-
GM may be protracted and take longer than normalization
of peripheral blood counts and marrow cellularity; how-
ever, they do not allow conclusions with regard to the
extent of damage and the degree of reconstitution of the
true stem cell compartment. In addition, neither CD34+
cells nor CFU-GM numbers have been reported as suitable
parameters to predict engraftment after unmanipulated allo-
geneic transplant.4–7 In aplastic anemia, which is charac-
terized by greatly depleted progenitor and stem cell com-
partments, we and others have observed only a partial
restoration of the number of LTC-IC and committed pro-
genitor cells, despite full recovery of PB counts after
immunosuppressive therapy;8 a numerical defect in these
cells persists even years after the initial successful treat-
ment.9,10 The causes for the inability to regenerate a normal
stem cell pool are not clear on the cellular level. A sus-
tained quantitative defect in the progenitor cell compart-
ment despite normal graft function after BMT may suggest
either intrinsic inability of a limited stem cell pool to
expand (only less than 1/200 of the donor hematopoietic
system is allografted), or a stromal defect reducing the
‘seeding efficiency’ and thus impairing the expansion.11–13
Indeed, a tremendous expansion of the allografted stem
cells would be needed to restore a normal LTC-IC fre-
quency. With the exception of a few recent studies,14,15
attempts at in vitro expansion of stem cells have been
unsuccessful.16,17 Recently, it has been reported that telo-
mere shortening occurs during in vitro and in vivo expan-
sion of hematopoietic stem cells, suggesting that the ability
to proliferate may be limited.18 After transplant, a signifi-
cant reduction of telomere length has been documented, and
this phenomenon may impair stem cell long-term rep-
licative capacity.19–21 Impaired function of stromal cells
supporting maintenance and proliferation of hematopoietic
progenitor and stem cells may also be responsible for their
long-lasting quantitative defect: chemotherapy and radio-
therapy have both been reported to induce a long-lasting
impairment in marrow stroma function.22–24
Unlike murine models, where hematopoietic stem cells
can be measured using in vivo competitive repopulation
assays, only a few methods exist for the measurement of
human stem cells. Assessment of the repopulating capacity
of early hematopoietic progenitors can be indirectly perfor-
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med utilizing pre-CFU or LTC-IC assays.6,25 At present,
LTC-IC are believed to be the best in vitro surrogate of the
stem cells which allow long-term engraftment after trans-
plant.26,27 Recently, deficient reconstitution of BM LTC-IC
after allogeneic BMT has been reported.9,10 Although LTC-
IC can also be measured in the peripheral blood, to our
knowledge no study of long-term reconstitution of circulat-
ing early hematopoietic progenitors has been reported so
far. As compared to the determination in BM, a PB-based
LTC-IC assay has several obvious advantages, which are
related to inaccuracy due to the variable dilution of marrow
samples with blood, difficult assessment of marrow cellu-
larity and limitation in frequent BM sampling. To investi-
gate the stem compartment after transplant and to assess
the value of the measurement of LTC-IC in peripheral
blood, we have checked the number of stem cells and com-
mitted progenitors in transplanted patients in comparison
with normal subjects, by measuring LTC-IC, CFU-GM and
CD34+ cells concurrently in BM and PB.
Materials and methods
Specimen collection
Bone marrow (BM) and peripheral blood (PB) samples
were obtained after informed consent from 37 bone marrow
donors and 25 patients who had been successfully allo-
transplanted with unmanipulated marrow from an HLA-
identical sibling. Allotransplanted patients included one
patient with severe aplastic anemia (SAA), 10 with acute
myeloid leukemia (AML) and 14 with chronic myeloid
leukemia (CML) (Table 1). There were 13 females and 12
Table 1 Characteristics of bone marrow transplanted patients
UPN Age Gender Disease Mononuclear cells CFU-GM aGVHD cGVHD CMV
patient/donor infused 3108/kg infused 3104/kg grade grade infection
4 31 F/F SAA 3.70 4.58 2 3 no
5 17 M/M AML 3.20 4.25 1 0 no
6 32 F/M CML 3.70 6.12 0 0 no
7 15 F/F AML 4.60 7.10 1 0 no
8 23 F/F CML 2.71 2.91 2 1 yes
9 17 F/M AML 3.10 3.97 2 0 no
10 25 F/F CML 3.40 4.62 0 1 yes
12 37 F/F CML 1.90 2.49 0 1 no
13 21 M/F CML 2.70 3.76 2 0 no
15 20 M/F CML 3.30 NA 1 3 no
16 36 M/M CML 2.70 NA 0 3 no
19 51 F/M AML 3.80 NA 1 0 no
22 35 M/F AML 1.90 NA 0 3 no
24 20 F/F AML 2.80 NA 1 0 no
33 45 F/F AML 2.80 NA 0 1 yes
45 19 M/M CML 3.60 1.65 0 0 yes
46 35 M/F CML 1.30 0.90 1 0 yes
49 38 F/M CML 2.60 2.70 0 3 no
61 19 F/M CML 1.40 1.40 0 1 yes
68 17 M/F CML 1.74 2.90 0 1 no
75 45 M/F AML 2.10 1.60 3 1 yes
78 33 M/F CML 2.00 1.83 2 3 yes
82 16 F/F AML 2.60 2.80 0 1 no
91 50 M/F CML 1.60 NA 2 3 no
95 38 M/M AML 2.40 3.10 1 3 yes
M = male; F = female; SAA = severe aplastic anemia; AML = acute myeloid leukemia; CML = chronic myeloid leukemia; NA = not available.
males, with a median age of 31 years (range 15–51).
Patients were infused with a median number of
2.72 · 108/kg mononuclear cells (range 0.9–7.12) and
2.90 · 104/kg (range 1.3–4.6) granulocyte–macrophage
colony-forming cells (CFU-GM). All patients were con-
ditioned with the BUCY2 regimen, except the patient with
SAA who received only cyclophosphamide (200 mg/kg);
no patient received prophylactic growth factors after BMT.
The median interval between BMT and the present analysis
was 4 years (range 1–8). At the time of testing, all trans-
planted patients had normal blood counts and bone marrow
cellularity (median value: 70% with a range 50–100%) with
a normal distribution of all hematopoietic lineages (Table
2).
Cytogenetics
In gender mismatched transplants, the engraftment was
documented by cytogenetic analysis according to the stan-
dard GTG-banding technique.
Flow cytometry analysis
Phycoerythrin (PE)-conjugated monoclonal antibody
(moAb) to CD34 (clone HPCA-1; Becton Dickinson,
Mountain View, CA, USA) was used to identify CD34+
cells. BM or PB samples were diluted to a white blood cell
(WBC) count of about 2 · 104/ml and stained with the
moAb for 20 min at 4° C. After staining, samples were sub-
jected to red blood cell lysis with ammonium chloride
buffer (Ortho, Raritan, NJ, USA) and washed with phos-
phate-buffered saline. Flow cytometry was performed using
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Table 2 Characteristics of bone marrow transplanted patients at the time of study
UPN Time from WBC Plt BM BM CD34+ PB CD34+ BM CFU-GM PB CFU-GM BM LTC-IC PB LTC-IC
transplant 3109/l 3109/l cellularity
(years) (%) 3105 mononuclear cells
4 8 7.9 220 70 400 50 10.8 4.25 0.140 0.010
5 7 5.0 175 80 1400 111 51.0 21.25 1.020 0.370
6 7 6.9 274 70 200 69 6.1 10.25 0.010 0.080
7 7 5.4 145 90 500 137 17.5 14.00 0.250 0.040
8 6 4.1 124 70 594 100 ND 8.75 ND 0.190
9 5 6.9 201 80 400 54 40.2 7.25 0.160 0.090
10 5 6.2 185 100 700 172 31.0 10.00 ND 0.035
12 5 4.6 158 90 400 153 18.0 6.25 0.400 0.020
13 4 5.1 110 70 900 149 27.6 15.50 0.510 0.020
15 4 3.7 128 70 600 85 7.7 10.00 ND 0.020
16 4 7.4 357 80 400 97 24.6 11.00 0.150 0.060
19 4 6.0 214 100 1300 52 48.4 8.50 0.810 ND
22 4 5.0 117 100 277 158 14.0 8.50 0.015 ND
24 3 6.6 235 90 800 102 44.2 11.50 0.500 0.095
33 3 3.6 197 100 700 167 23.5 16.25 0.350 0.010
45 3 6.1 163 90 1100 74 25.2 4.25 0.520 0.140
46 2 7.5 418 70 200 98 10.8 7.75 0.100 0.040
49 2 3.8 124 70 ND 52 ND 5.00 ND 0.040
61 2 4.7 228 90 600 80 30.6 5.50 0.260 0.045
68 2 9.5 162 70 100 119 3.0 11.25 0.040 0.120
75 2 7.6 143 50 ND 145 2.7 9.50 0.100 0.035
78 2 5.1 159 100 300 55 8.5 3.50 0.120 0.030
82 1 3.8 212 50 ND 109 ND 5.75 ND 0.060
91 1 6.6 201 80 ND ND ND ND 0.172 ND
95 1 5.8 148 100 ND ND ND ND 0.081 ND
a flow cytometer (Cytoron Absolute, Ortho Diagnostic
Systems) equipped with the ARS software (Ortho Diagnos-
tic Systems). During acquisition, a threshold was set on
forward light scatter to exclude cell debris from analysis.
A rectangular analysis region on sideward light scatter was
drawn to include all MNCs for determinations of CD34-
expressing cells, and live gate acquisition was performed
on cellular events that fell into that region. Ten thousand
events were acquired in the live gate, with a minimum of
60 000 events in the entire population.
Cell separation
BM was aspirated from the posterior iliac crest into
syringes containing Iscove’s modified Dulbecco’s medium
(IMDM) supplemented 1:10 with heparin (O’Neil and Feld-
man, St Louis, MO, USA). Mononuclear cells (MNC) from
BM and PB were isolated by density gradient centrifugation
using lymphocyte separation medium (Organon, Durham,
NC, USA). After washing with Hanks’ balanced salt sol-
ution (HBSS), cells were resuspended in IMDM sup-
plemented with 5% fetal calf serum (FCS). HBSS, IMDM
and FCS were purchased from Life Technologies, Gaithers-
burg, MD, USA.
Hematopoietic colony assay
Isolated BM and PB cells were plated in methylcellulose
(Stem Cell Technologies, Vancouver, Canada) at a concen-
tration of 2 · 105 cells/ml of medium (35 mm dishes; 1 ml
of medium/dish). The growth factor cocktail consisted of
10 ng/ml IL-3, 50 ng/ml G-CSF, 50 ng/ml GM-CSF, 20
ng/ml stem cell factor (SCF) and 2 U/ml erythropoietin
(EPO) (Amgen, Thousand Oaks, CA, USA). All cultures
were performed in duplicate. For estimation of circulating
progenitors per milliliter, the following equation was used:
LTC-IC/ml = LTC-IC/105 MNC · WBC/ml · %MNC/104.
LTC-IC assay
PB and BM MNC were plated on irradiated (15 Gy of 250
kV rays) allogeneic stromal cells (3 · 104/cm2) at cell den-
sities varying from 1 · 106 to 5 · 106 per well. To ensure
consistency in all experiments, stromal cells from only four
normal donors were used, and these layers showed compa-
rable feeder function as measured by the number of LTC-
IC grown from BM and PB of controls. At least three and
often more cell concentrations were applied on pre-estab-
lished irradiated stromal feeder layers. Culture medium
consisted of long-term stem cell medium (LTC; Stem Cell
Technologies) supplemented with 1 · 10 - 6 mol/l hydrocort-
isone sodium hemisuccinate (Sigma, St Louis, MO, USA).
These cultures were maintained at 37 ° C for 3 days and then
switched at 33 ° C for 5 weeks with weekly withdrawal of
half of the medium, which was replaced by fresh LTC
medium. At the end of the 5 weeks, all nonadherent cells
were removed and combined with cells harvested from the
adherent fraction by trypsinization; these cells were then
washed three times and assayed for their CFU-GM content
in the methylcellulose colony assay as described above. The
method we used to calculate LTC-IC number is described
at the end of the next section.
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Figure 1 Limiting dilution analysis. Bone marrow cells from five
representative transplanted patients and from five normal controls were
serially diluted and plated on irradiated allogeneic bone marrow stroma.
The proportion of wells containing secondary colonies after 5 weeks of
long-term culture was assessed and the absolute frequency of LTC-IC was
determined at the cell dilution with <37% negative wells according to
the Poisson equation.
Limiting dilution analysis
BM and PB MNC were cultured in 96-well flat bottom
plates containing pre-irradiated bone marrow allogeneic
stroma. At each dilution, 24 wells were seeded. After 5
weeks, wells were overlaid with semisolid medium contain-
ing the cocktail of growth factors described above. The fre-
quency of LTC-IC was calculated by determining the cell
dilution that resulted in <37% negative wells according to
the Poisson equation (m = 21/f lnP0, where m is the fre-
quency of clonogenic cells, f is the number of cells seeded
into each well, ln is the natural log, and P0 is the proportion
of empty wells). The clonogenic capacity of a single LTC-
IC was measured as the mean number of colonies per posi-
tive wells at dilution where the proportion of empty wells
was .0.75, and the probability of each well containing the
progeny of a single cell was .85%, equivalent to single
hit kinetics (one LTC-IC/well), according to the gamma
distribution.28 The clonogeneic capacity of a single LTC-
IC was also calculated by dividing the number of colonies
derived from bulk cultures by the frequency of LTC-IC
(Figure 1). By limiting dilution analysis we determined that
from normal donors a median of 3.5 colonies (range 1–24)
were generated by a single LTC-IC (n = 15, data not
shown). The clonogenic potential of LTC-IC in vitro from
10 transplanted patients was lower than normal donors, but
not statistically different (P . 0.5). Since in the LTC-IC
assay the relation between cell input and the output of sec-
ondary colonies after a 5 week culture was linear (Figure
2), for cultures in which the limiting dilution analysis was
not possible because of a limited cell number, the number
of clonogenic cells was converted to the absolute number
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Figure 2 Relationship between day 1 cell input in long-term culture and
number of secondary colonies measured after 5 weeks of culture. Five
representative transplanted patients and five normal controls.
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Figure 3 Hematopoietic progenitors in bone marrow of transplanted
patients and normal controls. Total bone marrow nucleated cells (BMNC)
were used for flow cytometric evaluation of CD34+ cells; bone marrow
mononuclear cells (BMMNC) were used for colony-forming cells (CFU-
GM) and for long-term culture initiating cell (LTC-IC) measurement. Each
dot represents a subject studied.
of LTC-IC by dividing the number of secondary CFU-GM
in bulk culture by the calculated in vitro clonogenicity.
Statistical analysis
All results were expressed as mean 6 standard error of the
mean (s.e.m.). Differences between groups were evaluated
using the Student’s t-test. Correlation between variables
was assessed using Pearson’s linear regression. The gamma
distribution was calculated using the GAMMADIST func-
tion in Microsoft Excel version 5.0 (Wokingham, UK).
Results
Marrow CD34+ cells, CFU-GM and LTC-IC in
transplanted patients
BM and PB total nucleated cells (TNC) were used for flow
cytometry evaluation of CD34+ cells, while mononuclear
cells were used for the measurement of primary and sec-
ondary CFU-GM. All transplanted patients had normal PB
leukocyte counts and BM cellularity at the time of the
analysis (Table 2), and showed complete engraftment at the
cytogenetic level when this test was informative. CD34+
cells from BM were decreased three- to four-fold in trans-
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Table 3 Stem cells and hematopoietic progenitors in bone marrow of transplanted patients
CD34+ CFU-GM LTC-IC
3105 total nucleated cells 3105 mononuclear cells 3105 mononuclear cells
Normal subjects 1976 6 229 55.02 6 4.13 2.465 6 0.370
n = 25 n = 37 n = 20
Transplanted patients 594 6 85 22.27 6 3.35 0.285 6 0.060
n = 20 n = 20 n = 20
Pa ,0.0001 ,0.0001 ,0.0001
aStudent’s t-test.
Table 4 Approximate percentage of progenitor cells in BM and PB
of normal subjects and transplanted patients
Normal Transplanted
subjects patients
Bone marrow
CD34+ a 2% 0.6%
CFU-GMb 0.05% 0.02%
LTC-ICb 0.002% 0.0003%
Peripheral blood
CD34+a 0.1% 0.1%
CFU-GMb 0.015% 0.010%
LTC-ICb 0.0004% 0.00007%
a% of total nucleated cells.
b% of mononuclear cells.
planted patients compared to normal donors (594 6 85/105
total nucleated cells vs 1976 6 229; P , 0.0001). Simi-
larly, primary CFU-GM from BM were decreased 2.1-fold
(22.3 6 3/105 MNC plated vs 55 6 4; P , 0.0001). The
depletion of the LTC-IC compartment appeared to be more
pronounced: we observed an eight-fold decrease of early
progenitor cells, measured as LTC-IC, in the BM of trans-
planted patients compared to normal donors
(0.28 6 0.06/105 MNC plated vs 2.46 6 0.37: P , 0.0001)
(Tables 3 and 4, Figure 3). Marrow LTC-IC cell number
in transplanted patients was not influenced by the number
of CFU-GM infused: using as a cut-off the median value
(2.93 · 104/kg CFU-GM), there was no difference in LTC-
IC frequency between the groups of patients who had
received fewer or more CFU-GM (P = 0.74). Any grade
of acute or chronic graft-versus-host disease as well as
cytomegalovirus infection did not affect LTC-IC frequency
after BMT (P = 0.38, P = 0.06 and P = 0.43, respectively).
In addition, we found that LTC-IC cell number in BM
showed a good correlation with concurrently determined
BM CD34+ cells and CFU-GM (P , 0.0001): CFU-GM vs
CD34+ cells (r = 0.786), LTC-IC vs CD34+ (r = 0.954),
and LTC-IC vs CFU-GM (r = 0.810).
Circulating CD34+, CFU-GM and LTC-IC in
transplanted patients
Quantitative assessment of LTC-IC in the BM may be
affected by several factors such as a variable level of con-
tamination with blood or heterogeneous distribution of
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Figure 4 Circulating hematopoietic progenitors of transplanted patients
and normal controls. Total peripheral blood nucleated cells (PBNC) were
used for flow cytometric evaluation of CD34+ cells; peripheral blood
mononuclear cells (PBMNC) were used for colony-forming cells (CFU-
GM) and for long-term culture initiating cell (LTC-IC) measurement. Each
dot represents a subject studied.
cellularity within the aspirated marrow area. We therefore
measured CD34+, CFU-GM and LTC-IC cell numbers in
PB from transplanted patients and normal subjects. The
measured numbers were adjusted for white blood cell count
and the proportion of blood mononuclear cells as described
in the section Hematopoietic Colony Assay in Materials
and methods. We also evaluated the absolute frequency of
CD34+, CFU-GM and LTC-IC per milliliter of blood; the
two measurements had a good correlation (P , 0.0001). At
variance with the findings in BM, the number of circulating
CD34+ cells was similar in transplanted patients and normal
donors (103.8 6 8.4 vs 97.6 6 7.7) and primary CFU-GM
were only slightly decreased (9.3 6 0.9 vs 15.6 6 0.9). By
contrast, a five-fold decrease of LTC-IC was documented
in PB (0.074 6 0.018 vs 0.374 6 0.043) (Table 5, Figure
4). We found that PB LTC-IC cell number correlated with
concurrently determined BM LTC-IC number (P = 0.003),
but not with BM CFU-GM and CD34+ cells.
Effect of time elapsed from transplant on LTC-IC number
in blood and bone marrow
BM and PB CD34+ and CFU-GM cell numbers showed a
progressive improvement in the first 2–5 years after trans-
plant. Although the median number was reduced as com-
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Table 5 Stem cells and hematopoietic progenitors in peripheral blood of transplanted patients
CD34+ CFU-GM LTC-IC
3105 TNC 3 ml 3105 MNC 3 ml 3105 MNC 3 ml
Normal subjects 97.6 6 7.7 5656 6 474 15.6 6 0.9 334 6 38.4 0.37 6 0.04 8.11 6 1.24
n = 25 n = 20 n = 21
Transplanted patients 103.8 6 8.4 6191 6 603 9.3 6 0.9 246 6 28.7 0.074 6 0.02 1.94 6 0.49
n = 23 n = 23 n = 21
Pa 0.59 0.49 ,0.001 0.07 ,0.001 ,0.001
aStudent’s t-test.
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Figure 5 Number of BM (a) and PB (b) LTC-IC according to time from
transplant. Grey area: number of LTC-IC in 20 normal donors.
pared to normal subjects, there was some overlap with the
normal range that was not detected when LTC-IC were
evaluated (data not shown). The BM LTC-IC compartment
was markedly depleted during the first 2 years from trans-
plant. Between 2 and 5 years from transplant, the mean
marrow LTC-IC cell number tended to rise (0.124 6 0.026
vs 0.371 6 0.083 before and after 2 years, respectively; P
= 0.018), but the majority of patients showed LTC-IC num-
bers markedly below those seen in normal controls. There
was no further improvement in LTC-IC number up to 8
years after transplantation (Figure 5). Unlike those in BM,
circulating LTC-IC did not improve with time after trans-
plant: LTC-IC were only slightly higher, but not statisti-
cally different, 5 years after transplant (1.34 6 0.38 vs
2.25 6 0.71 before and after 2 years, respectively; P =
0.40).
In vitro and in vivo proliferative potential of LTC-IC
from transplanted patients and normal subjects
Stem cell clonogenic capacity in vivo was indirectly evalu-
ated by dividing the number of LTC-IC by the number of
CFU-GM. Using this proportion, we documented that in
transplanted patients (n = 17) 14.43 6 1.89 marrow LTC-
IC were necessary to obtain 103 CFU-GM, in comparison
to 40.75 6 20 in healthy subjects (n = 14; P = 0.014), sug-
gesting that in vivo LTC-IC in transplanted patients have
higher clonogenic capacity than controls (LTC-IC/CFU-
GM 1/70 vs 1/25 in transplanted patients and healthy sub-
jects, respectively). Similar results were observed in periph-
eral blood: 8.39 6 1.68 LTC-IC/103 CFU-GM (n = 21) vs
27.09 6 3.29 (n = 18) in transplanted patients and in
healthy subjects, respectively (P , 0.001). To determine
the proportion of CFU-GM in relation to the stem cell com-
partment in vitro, we also measured the clonogenic capacity
of individual LTC-IC. In addition to the direct determi-
nation by limiting dilution analysis, where decreasing num-
bers of cells are plated to define the concentration achieving
single hit kinetics by the Poisson distribution, an indirect
technique was also applied. In this method the clonogenic
capacity of LTC-IC was obtained by dividing the number
of colonies derived from bulk cultures by the frequency of
LTC-IC. Using both methods, the median number of CFU-
GM per LTC-IC was about 2.5 (n = 10) and not signifi-
cantly different from normal controls (n = 15; P = 0.3)
(Table 6). We also calculated the frequency of marrow
LTC-IC in relation to the CD34+ cell compartment: the
number of LTC-IC/105 MNC was divided by CD34+/105
MNC. Marrow LTC-IC within the compartment of CD34+
did not show significant differences between transplanted
patients and normal controls: 0.198 6 0.020 LTC-IC/103
CD34+ vs 0.275 6 0.077 (P = 0.19).
Discussion
The analysis of stem and progenitor cell compartments after
allogeneic bone marrow transplant may give clues on the
potential and kinetics of stem cell expansion which starts
from the finite number of cells used for a bone marrow
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Table 6 In vitro secondary CFU-GM production from single LTC-IC by limiting dilution analysis
UPN Number of P for each well Number of secondary Measured Calculated
positive wellsa containing a single CFU-GM per clonogenicityb clonogenicityc
clonogenic cella positive well
12 6 0.91 1,1,2,3,5,7 2.9 3.1
19 6 0.89 1,2,4,5,5,8 3.8 3.3
22 3 0.90 1,2,5 2.43 1.95
33 8 0.95 1,2,2,3,3,3,4,5 2.77 2.68
45 7 0.93 1,3,4,5,6,8,9 4.8 4.3
46 4 0.90 1,1,1,3 1.3 1.5
61 5 0.89 1,1,1,1,7 1.99 2.69
75 5 0.89 1,1,1,1,2 1.08 1.82
91 9 0.91 1,1,1,1,2,2,3,3,4 1.84 1.945
95 4 0.95 1,3,4,5 3.08 2.12
Median 2.6 2.4
Range 1.08–4.8 1.5–4.3
Normal controls (n = 15)
Median 3.5 3.3
Range 1.2–8.1 1.8–6.7
aPositive wells at dilution where the proportion of empty wells was .0.75 and P for each well containing the progeny of a single cell was .0.85,
according to gamma distribution.
bClonogenicity was measured as mean of secondary CFU-GM per positive wells, adjusted according to the P for each well containing a single clono-
genic cell.
cClonogenicity was calculated dividing secondary CFU-GM derived from bulk cultures by the frequency of LTC-IC calculated using the Poisson equation.
graft. Our study shows that despite full hematologic recov-
ery, the number of the most immature hematopoietic cells
remains permanently below that observed in normal donors.
The results also suggest that a greatly and permanently
depleted stem cell compartment is compatible with suf-
ficient production of mature blood cells to cause full hema-
tological recovery. These findings are in agreement with
previous results showing deficient post-transplant recovery
of BM committed progenitors, measured as CD34+ cells or
as CFU-GM, and of stem cells, measured as LTC-IC.1–3
Markedly decreased numbers of BM and PB LTC-IC in
transplanted patients suggests that either the self-renewal
ability of hematopoietic stem cells is in some way impaired
or that a biologically determined limit of expansion of stem
cells does exist in vivo. In addition, the lack of correlation
between the number of repopulating cells transplanted and
the number of progenitors measured after recovery suggests
that the repopulation is attributable to a small number of
early progenitors. Recently, it has been hypothesized that
hematopoietic stem cells have only a limited replicative
potential (,100 divisions) and that 55 divisions can yield
4 · 1016 cells over a lifetime.29 Impairment of the self-
renewal capacity under conditions of a depleted stem cell
pool may explain the inability to restore the stem cell levels
while ensuring complete hematological recovery. This
possibility is consistent with our finding in vivo of lower
LTC-IC/CFU-GM ratios after transplant, and implies that
primitive cells tend to differentiate into committed progeni-
tor cells rather than to self-renew. Telomere shortening
after transplant also supports our conclusions: comparison
of telomere length concomitantly measured in peripheral
blood granulocytes from the donor and from the recipient
years after successful transplant revealed that telomere
length was significantly reduced in the recipients.19–21 It
was also documented that the extent of telomere shortening
after transplant was inversely correlated with the number
of stem cells infused, suggesting a reduction of their pro-
liferative drive.19 A possible upregulation of telomerase
activity in response to cytokine-induced proliferation may
only reduce, but not prevent, telomere shortening of hema-
topoietic cells after ex vivo expansion.18,22 All these obser-
vations may suggest that in transplanted patients the self-
renewal ability of hematopoietic stem cells in vivo during
bone marrow repopulation may be shifted towards differen-
tiation or maturation. Recently, in a murine model it has
been reported that LTC-IC expansive capacity is inversely
correlated with the number of infused LTC-IC, suggesting
that the repopulative stress does not reduce the long-term
repopulating activity of stem cells; nevertheless, such an
increased repopulating capacity is not sufficient to restore
a normal stem cell compartment.30 We found that in trans-
planted patients the clonogenic capacity of LTC-IC in vitro
is within the normal range; thus, there is an apparent dis-
crepancy between in vivo and in vitro studies. The discrep-
ancy could be due to a peculiar steady-state condition of
the transplanted stem cells. In the experimental in vitro sys-
tem, the proliferation kinetics of transplanted stem cells
seems identical to that of stem cells derived from normal
donors, while in vivo the type and concentration of
endogenously produced growth factors as well as a T cell-
mediated host tolerance to the graft may provide a signal
for expansion of more mature cell subsets after trans-
plant.31,32
We found that the deficiency in early hematopoietic cells
after BMT is less evident at the level of CD34+ and com-
mitted progenitor cells (measured as CFU-GM) than at the
level of more immature progenitors (measured as LTC-IC).
Indeed, the number of circulating CD34+ cells did not differ
from that measured in normal controls. As circulating
CD34+ cells constitute only a minor fraction of the total
CD34+ cell pool, this finding may indicate redistribution or
a shift of these cells into the periphery, possibly in response
LTC-IC deficiency after BMT
C Selleri et al
1036
to a higher demand and elevated growth factor levels. Our
results also imply that the number of CD34+ cells cannot
be used as a direct measure of the reconstituting ability of
hematopoietic progenitors (although it is the most fre-
quently used parameter). An alternative hypothesis is that
BM and PB CD34+ cells may derive from two different
stem cell pools. This hypothesis is supported by functional
differences detected between marrow and circulating
CD34+ cells, as well as by a shorter time required for
repopulation when peripheral stem cells are used for trans-
plant.33,34 At variance to CD34+ cells, LTC-IC were com-
parably depleted in marrow and peripheral blood, suggest-
ing that they represent members of a uniform stem cell
pool. Based on the correlation between the number of PB
and BM LTC-IC, it appears that enumeration of LTC-IC
in peripheral blood provides sufficient information for the
analysis of the stem cell compartment.
In conclusion, our data confirm a previous study on a
larger number of patients with a longer follow-up, showing
that the bone marrow stem cell compartment, as measured
by the LTC-IC assay, is deeply and permanently depressed
following allogeneic bone marrow transplant.9 In addition,
our study shows that circulating LTC-IC can be used to
measure the stem cell compartment after BMT. All data
indicate that a long-lasting deficiency of the most immature
progenitors does not preclude normal functioning of the
hematopoietic system, at least in a steady state condition.
It remains to be verified whether in conditions of increased
demand (infections, injuries, immunologic complications)
a depleted stem cell pool may lead to a secondary bone
marrow failure syndrome.
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